Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial
News Update

Share on Stocktwits


Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2.

In a news release, Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced that it has "enrolled its first patient from the U.S. for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19."

The firm advised that the Phase 2b/3 trial calls for the enrollment of 150 patients in total from all participating sites and that it has already enrolled 26 patients since the study commenced on August 5, 2020.

Algernon CEO Christopher J. Moreau stated, "We are very pleased to announce our first U.S. patient...We have also had steady enrollment from one of our international sites and as a result, we expect to reach 25% of our total target shortly."

AlgernonPharmaceuticals stated that its multinational human trial is named "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."

The Phase 2b part of the trial plans for the enrollment of 150 patients and if positive preliminary data is demonstrated, the clinical trial will move directly into a Phase 3 trial. The company said that Phase 2b study results will dictate the number of patients required for the Phase 3 trial in order to reach statistical significance.

Patients in the study will be randomized and be treated using an existing standard of care or standard of care plus Ifenprodil in either 60 mg or 120 mg doses for two weeks. During the trial, doctors will observe if there are improvements in several secondary endpoints including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation.

Algernon noted that it plans to provide an update in the near future as to the study's projected completion date along with details as to when the read out of the data will be available.

The firm explained that NP-120 (Ifenprodil) is "a N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) which prevents glutamate signaling." The company added that NMDA receptors are found on various tissues such as lung cells, T-cells, and neutrophils. The company stated "it believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively."


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Algernon Pharmaceuticals. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Algernon Pharmaceuticals. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Pharmaceuticals, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe